elosulfase alfa (Vimizim)
elosulfase alfa is an FDA-licensed reference biologic from BioMarin Pharmaceutical Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2014
Reference approved
Reference product
Vimizim elosulfase alfa
BioMarin Pharmaceutical Inc.
- Approved
- Feb 14, 2014
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for elosulfase alfa from the RCSB Protein Data Bank (PDB 4FDI).
Interactive biological assembly from PDB entry 4FDI. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for elosulfase alfa, in chronological order.
Reference approval
Approval date of the reference elosulfase alfa product.
12 yr 7 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
5 yr 6 mo ago
Frequently asked questions
Are there biosimilars approved for elosulfase alfa (Vimizim)?
No 351(k) biosimilars or interchangeable biosimilars referencing elosulfase alfa are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.